Home page Home page

Caprelsa
vandetanib

Package leaflet: Information for the patient Caprelsa 100 mg film-coated tablets Caprelsa 300 mg film-coated tablets vandetanib


image

imageThis medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.


In addition to this leaflet you will be given the Patient Alert Card, which contains important safety information that you need to know before you are given Caprelsa and during treatment with Caprelsa.


Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

breast cancer), mizolastine (used to treat allergies), Class IA and III antiarrhythmics (used to control heart rhythm).


Do not take Caprelsa if any of the above applies to you. If you are not sure, talk to your doctor.

Warnings and precautions

Talk to your doctor or pharmacist before taking Caprelsa:


What Caprelsa looks like and contents of the pack

Caprelsa 100 mg is a white round film-coated tablet with “Z100” imprinted on one side. Caprelsa 300 mg is a white oval-shaped film-coated tablet with “Z300” imprinted on one side.


Caprelsa comes in blister packs of 30 tablets.


Marketing Authorisation Holder Genzyme Europe B.V., Paasheuvelweg 25

1105 BP Amsterdam The Netherlands


Manufacturer


Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Ireland


For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:


België/Belgique/Belgien/ Luxembourg/Luxemburg Sanofi Belgium

Tél/Tel: + 32 (0)2 710 54 00

Magyarország SANOFI-AVENTIS Zrt. Tel: +36 1 505 0050


България

Swixx Biopharma EOOD Tел: +359 (0)2 4942 480

Malta

Sanofi S.r.l.

Tel: +39 02 39394275


Česká republika sanofi-aventis, s.r.o. Tel: +420 233 086 111

Nederland

Genzyme Europe B.V. Tel: +31 20 245 4000


Danmark

Sanofi A/S

Norge

sanofi-aventis Norge AS

Tlf: +45 45 16 70 00 Tlf: + 47 67 10 71 00


Deutschland

Sanofi-Aventis Deutschland GmbH Tel.: 0800 52 52 010

Tel. aus dem Ausland: +49 69 305 21 131

Österreich

sanofi-aventis GmbH Tel: + 43 1 80 185 - 0


Eesti

Swixx Biopharma OÜ Tel. +372 640 10 30

Polska

sanofi-aventis Sp. z o.o. Tel.: +48 22 280 00 00


Ελλάδα

sanofi-aventis AEBE

Τηλ: +30 210 900 16 00

Portugal

Sanofi – Produtos Farmacêuticos, Lda. Tel: +351 21 35 89 400


España

sanofi-aventis, S.A. Tel: +34 93 485 94 00

România

Sanofi Romania SRL Tel: +40 (0) 21 317 31 36


France

sanofi-aventis France Tél: 0 800 222 555

Appel depuis l’étranger: +33 1 57 63 23 23

Slovenija

Swixx Biopharma d.o.o. Tel: +386 1 235 51 00


Hrvatska

Swixx Biopharma d.o.o. Tel: +385 1 2078 500


Ireland

sanofi-aventis Ireland Ltd. T/A SANOFI Tel: +353 (0) 1 403 56 00

Slovenská republika Swixx Biopharma s.r.o. Tel.: +421 2 208 33 600


Ísland

Vistor hf.

Sími: +354 535 7000

Suomi/Finland

Sanofi Oy

Puh/Tel: + 358 (0) 201 200 300


Italia

Sanofi S.r.l.

Tel: + 800 536 389


Κύπρος

C.A. Papaellinas Ltd.

Τηλ: +357 22 741741

Sverige

Sanofi AB

Tel: +46 (0)8 634 50 00


Latvija

Swixx Biopharma SIA Tel: +371 6 616 47 50

United Kingdom (Northern Ireland) sanofi-aventis Ireland Ltd. T/A SANOFI Tel: +44 (0) 800 035 2525


Lietuva

Swixx Biopharma UAB Tel. +370 5 236 91 40


This leaflet was last revised in

This medicine has been given ‘conditional approval’. This means that there is more evidence to come about this medicine.

The European Medicines Agency will review new information on the medicine at least every year and this leaflet will be updated as necessary.